Generate Biomedicines is exploding higher as investors position themselves ahead of the expiration of the company's post-IPO lock-up period, which is set to conclude this Wednesday. The stock reached a new 52-week high of $22.67 during the session, significantly outperforming its 50-day moving average by 40%. While the broader biotechnology sector saw various regulatory updates and FDA activity regarding other firms, the move in Generate Biomedicines is specifically tied to the anticipated release of shares held by company insiders and early investors.